Differential expression and activity of matrix metalloproteinase-2 and-9 in the calreticulin deficient cells

被引:20
作者
Wu, Min
Massaeli, Hamid
Durston, Melanie
Mesaeli, Nasrin
机构
[1] Univ Manitoba, St Boniface Gen Hosp, Inst Cardiovasc Sci,Res Ctr, Dept Biochem & Med Genet,Fac Med,Div Stroke & Vas, Winnipeg, MB R2H 2A6, Canada
[2] Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada
基金
加拿大健康研究院;
关键词
calreticulin; matrix metal loproteinase-2; MMP-9; MTI-MMP; P13; kinase; MEK;
D O I
10.1016/j.matbio.2007.02.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Calreticulin is an endoplasmic reticulum protein important in cardiovascular development. Deletion of the calreticulin gene leads to defects in the heart and the formation of omphaloceal. These defects could both be due to changes in the extracellular matrix composition. Matrix metalloprotemases (MMP)-2 and MMP-9 are two of the MMPs which are essential for cardiovascular remodelling and development. Here, we tested the hypothesis that the defects observed in the heart and body wall of the calreticulin null embryos are due to alterations in MMP-2 and MMP-9 activity. Our results demonstrate that there is a significant decrease in the MMP-9 and increase in the MMP-2 activity and expression in the calreticulin deficient cells. We also showed that there is a significant increase in the expression level of membrane type-1 matrix metalloprotemase (MT1-MMP). In contrast, there was no change in the tissue inhibitor of matrix metalloproteinase (TIMP)-1 or -2 in the calreticulin deficient cells as compared to the wild type cells. Interestingly, the inhibition of the MEK kinase pathway using PD98059 attenuated the decrease in the MMP-9 mRNA with no effect on the MMP-2 mRNA level in the calreticulin deficient cells. Furthermore, PI3 kinase inhibitor decreased the expression of both the MMP-2 and MMP-9. This study is the first report on the role of calreticulin in regulating MMP activity. (c) 2007 Elsevier B.V./International Society of Matrix Biology. All rights reserved.
引用
收藏
页码:463 / 472
页数:10
相关论文
共 37 条
[1]   The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury [J].
Bornstein, P ;
Agah, A ;
Kyriakides, TR .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (06) :1115-1125
[2]   Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase:: associated activation of gelatinase A, gelatinase B and collagenase 3 [J].
Cowell, S ;
Knäuper, V ;
Stewart, ML ;
d'Ortho, MP ;
Stanton, H ;
Hembry, RM ;
López-Otín, C ;
Reynolds, JJ ;
Murphy, G .
BIOCHEMICAL JOURNAL, 1998, 331 :453-458
[3]   Matrix metalloproteinase inhibition after myocardial infarction - A new approach to prevent heart failure? [J].
Creemers, EEJM ;
Cleutjens, JPM ;
Smits, JFM ;
Daemen, MJAP .
CIRCULATION RESEARCH, 2001, 89 (03) :201-210
[4]   ERKI-2 and p38 MAPK regulate MMP/TIMP balance and function in response to thrombospondin-1 fragments in the microvascular endothelium [J].
Donnini, S ;
Morbidelli, L ;
Taraboletti, G ;
Ziche, M .
LIFE SCIENCES, 2004, 74 (24) :2975-2985
[5]   New functions for the matrix metalloproteinases in cancer progression [J].
Egeblad, M ;
Werb, Z .
NATURE REVIEWS CANCER, 2002, 2 (03) :161-174
[6]   Calnexin, calreticulin, and ERp57 - Teammates in glycoprotein folding [J].
Ellgaard, L ;
Frickel, EM .
CELL BIOCHEMISTRY AND BIOPHYSICS, 2003, 39 (03) :223-247
[7]   Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines.: A process repressed through RAS/MAP kinase signaling pathways [J].
Esparza, J ;
Vilardell, C ;
Calvo, J ;
Juan, M ;
Vives, J ;
Urbano-Márquez, A ;
Yagüe, J ;
Cid, MC .
BLOOD, 1999, 94 (08) :2754-2766
[8]   Identification of an N-domain histidine essential for chaperone function in calreticulin [J].
Guo, L ;
Groenendyk, J ;
Papp, S ;
Dabrowska, M ;
Knoblach, B ;
Kay, C ;
Parker, JMR ;
Opas, M ;
Michalak, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (50) :50645-50653
[9]  
Hofmann UB, 2000, INT J CANCER, V87, P12, DOI 10.1002/1097-0215(20000701)87:1<12::AID-IJC3>3.0.CO
[10]  
2-A